VBC103 / VelaVigo, Avenzo Therap - LARVOL DELTA

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate (PRNewswire) - "VelaVigo will maintain rights for Greater China and plans to collaborate with Avenzo in global development....Under the terms of the agreement, VelaVigo will receive an upfront fee and potential near-term milestones upon option exercise by Avenzo of up to $50 million. In addition, VelaVigo is eligible to receive future potential development, regulatory, and commercial milestone payments of up to approximately $750 million in total, as well as tiered royalties on sales in Avenzo's territory. An Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (FDA) and Chinese National Medical Products Administration (NMPA) in 2025."

Licensing / partnership • New trial • Solid Tumor

VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond (AACR 2024) - "The therapeutic potential of targeting Trop2 or Nectin4 has been demonstrated through the approval of Trodelvy™ (Sacituzumab govitecan; SG) and Padcev™ (Enfortumab Vedotin; EV). VBC103 also exhibited excellent developability based on plasma stability and other stress test data, which suggests it a good candidate in future CMC development.In summary, VBC103, with its unique bispecific design and differentiated features in affinity, valency, linker-payload, has shown promising potential as a first-in-class ADC candidate. Discovery studies have revealed favorable efficacy and toxicity profiles, supporting advancing VBC103 into clinical trials."

Late-breaking abstract • Bladder Cancer • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • Urothelial Cancer • NECTIN4 • TACSTD2